drugset / Trial / NCT06118905
Preserving Geriatric Muscle With an Osteoporosis Medication
RandomizedParallel-groupDouble-blindTreatment
Summary
Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.
Timeline
- Start
- 2024-02-08
- Primary completion
- 2029-02-28
- Completion
- 2029-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denosumab | Monoclonal antibody | 60 mg | Subcutaneous |
| Comparator | Zoledronic acid | Other / unclassified | 5 mg | Intravenous |